专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2341923A2 PHARMACEUTICAL COMPOSITION COMPRISING COENZYME Q10 审中-公开
标题翻译：与辅酶Q10的药物组合物
公开(公告)号：EP2341923A2
公开(公告)日：2011-07-13
申请号：EP09817367.7
申请日：2009-09-25
申请人： Sharma, Saumya , Thakur, Srinath , Setty, Swati , Kulkarni, Rajesh , Kulkarni, Shirishkumar
发明人： Sharma, Saumya , Thakur, Srinath , Setty, Swati , Kulkarni, Rajesh , Kulkarni, Shirishkumar
IPC分类号： A61K38/43
CPC分类号： A61K8/355 , A61K9/0063 , A61K31/122 , A61Q11/00
摘要： A pharmaceutical composition for administration in gum pockets caused by periodontal disease, consisting: coenzyme Q10 and pharmaceutically acceptable excipients selected from the group comprising solubilizer; biodegradable polymer; solvent, and/or combinations thereof. A process for making a pharmaceutical composition for administration in pockets in gums caused by periodontal disease, consisting: coenzyme Q10 and pharmaceutically acceptable excipients wherein the solubilizer was dissolved in the solvent with stirring to obtain a clear solution followed by addition of the biodegradable polymer to this solution with stirring to obtain a clear solution; to this solution CoQ10 was added with vortexing to form a uniform suspension.

2. 发明申请

WO2009047802A2 NOVEL COLON TARGETED MODIFIED RELEASE BIOADHESIVE FORMULATION OF 5-AMINO SALICYLIC ACID OR ITS SALTS AND METABOLITES THEREOF 审中-公开
标题翻译：新颖的针对性的修饰释放生物活性配制5-氨基磺酸或其盐及其代谢物
公开(公告)号：WO2009047802A2
公开(公告)日：2009-04-16
申请号：PCT/IN2008000654
申请日：2008-10-08
申请人： LUPIN LTD , KULKARNI SHIRISH KUMAR , KULKARNI RAJESH , JADHAV PANDARINATH , BADHE UMESH , GUPTA SUSHMA
发明人： KULKARNI SHIRISH KUMAR , KULKARNI RAJESH , JADHAV PANDARINATH , BADHE UMESH , GUPTA SUSHMA
IPC分类号： A61K9/20 , A61K9/28 , A61K31/606 , A61P29/00
CPC分类号： A61K9/205 , A61K9/2054 , A61K9/2846 , A61K31/606
摘要： The present invention relates to a colon targeted modified release bioadhesive pharmaceutical composition of 5-amino salicylic acid or a pharmaceutically acceptable salt or enantiomer or polymorph or metabolites thereof, optionally one or more hydrophilic or hydrophobic release controlling agent(s) and pharmaceutical acceptable excipient(s), and the process of preparing it.
摘要翻译：本发明涉及5-氨基水杨酸或其药学上可接受的盐或对映异构体或其多晶型物或其代谢物，任选的一种或多种亲水或疏水性释放控制剂和药学上可接受的赋形剂的结肠靶向改性释放生物粘附性药物组合物 s）及其准备过程。

3. 发明申请

WO2009047801A1 THERAPEUTIC COMBINATIONS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 审中-公开
标题翻译：用于治疗胃肠疾病的治疗组合物和组合物
公开(公告)号：WO2009047801A1
公开(公告)日：2009-04-16
申请号：PCT/IN2008/000653
申请日：2008-10-08
申请人： LUPIN LIMITED , JAHAGIRDAR, Harshal , BADHE, Umesh , THOMAS, Jisha , KULKARNI, Rajesh , KULKARNI, Shirishkumar
发明人： JAHAGIRDAR, Harshal , BADHE, Umesh , THOMAS, Jisha , KULKARNI, Rajesh , KULKARNI, Shirishkumar
IPC分类号： A61K31/44 , A61K31/437 , A61K9/20 , A61K9/24 , A61K9/52 , A61P29/00 , A61P31/04
CPC分类号： A61K9/5073 , A61K9/0065 , A61K9/2077 , A61K9/209 , A61K9/2846 , A61K9/5026 , A61K31/00 , A61K31/437 , A61K31/44 , A61K45/06 , A61K2300/00
摘要： The present invention relates to pharmaceutical combinations of mesalamine or a pharmaceutically acceptable salt or prodrugs thereof and rifaximin or a pharmaceutically acceptable salt or prodrugs thereof to treat patients suffering from inflammatory bowel disease (IBD) and/or irritable bowel syndrome (IBS). The invention also relates to additive and/or synergistic combinations of mesalamine and rifaximin.
摘要翻译：本发明涉及美沙拉嗪或其药学上可接受的盐或前药及利福昔明或其药学上可接受的盐或前药的药物组合，用于治疗患有炎症性肠病（IBD）和/或肠易激综合征（IBS）的患者。本发明还涉及美沙拉嗪和利福昔明的添加剂和/或协同组合。

4. 发明申请

WO2010038239A2 PHARMACEUTICAL COMPOSITION COMPRISING COENZYME Q10 审中-公开
标题翻译：包含酵素的药物组合物Q10
公开(公告)号：WO2010038239A2
公开(公告)日：2010-04-08
申请号：PCT/IN2009000525
申请日：2009-09-25
申请人： SHARMA SAUMYA , THAKUR SRINATH , SETTY SWATI , KULKARNI RAJESH , KULKARNI SHIRISHKUMAR
发明人： SHARMA SAUMYA , THAKUR SRINATH , SETTY SWATI , KULKARNI RAJESH , KULKARNI SHIRISHKUMAR
IPC分类号： A61K8/35
CPC分类号： A61K8/355 , A61K9/0063 , A61K31/122 , A61Q11/00
摘要： A pharmaceutical composition for administration in gum pockets caused by periodontal disease, consisting: coenzyme Q10 and pharmaceutically acceptable excipients selected from the group comprising solubilizer; biodegradable polymer; solvent, and/or combinations thereof. A process for making a pharmaceutical composition for administration in pockets in gums caused by periodontal disease, consisting: coenzyme Q10 and pharmaceutically acceptable excipients wherein the solubilizer was dissolved in the solvent with stirring to obtain a clear solution followed by addition of the biodegradable polymer to this solution with stirring to obtain a clear solution; to this solution CoQ10 was added with vortexing to form a uniform suspension.
摘要翻译：一种由牙周病引起的口香糖口服药物组合物，包括：辅酶Q10和药学上可接受的赋形剂，选自增溶剂; 可生物降解聚合物; 溶剂和/或其组合。制备牙周疾病引起的牙龈袋中给药的药物组合物的方法，其包括：辅酶Q10和药学上可接受的赋形剂，其中在搅拌下将增溶剂溶解在溶剂中以获得澄清溶液，随后向其中加入生物可降解聚合物溶液搅拌以获得澄清溶液; 向该溶液中添加CoQ10以涡旋形成均匀的悬浮液。

5. 发明申请

WO2009008006A2 PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY 审中-公开
标题翻译：用于胃肠道给药的药物组合物
公开(公告)号：WO2009008006A2
公开(公告)日：2009-01-15
申请号：PCT/IN2008/000401
申请日：2008-06-24
申请人： LUPIN LIMITED , JAHAGIRDAR, Harshal, Anil , KULKARNI, Rajesh , KULKARNI, Shirishkumar
发明人： JAHAGIRDAR, Harshal, Anil , KULKARNI, Rajesh , KULKARNI, Shirishkumar
IPC分类号： A61K9/16 , A61K9/20
CPC分类号： A61K47/44 , A61K9/0065 , A61K9/0095 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2086 , A61K9/209 , A61K31/196 , A61K31/197 , A61K31/437 , A61K31/4402 , A61K31/606 , A61K31/635 , A61K31/655 , A61K31/785 , A61K38/12 , A61K47/32 , A61K47/34 , A61K47/38
摘要： A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/ fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.
摘要翻译：一种新型药物组合物，其包含治疗有效量的活性成分或其药学上可接受的盐或对映体或多晶型物，任选的一种或多种释放控制剂及其药学上可接受的赋形剂，其中所述组合物配制成增加所述药物组合物和/或活性成分在胃肠道中的停留时间。一种新型药物组合物，其包含至少两个实体，其中一个实体是即时释放/快速释放，另一个实体是控制释放的。包含至少两个实体的药物组合物，其中一个实体是立即释放/快速释放，另一个是生物粘附的。一种药物组合物，其包含：至少两个实体，其中一个实体被控制释放，另一个实体是生物粘附剂。所有三种组合物被配制以增加活性成分在胃肠道中的停留时间。在层中具有活性的多层组合物，其提供活性成分和层的即时释放或控制释放，从而在GI道中提供增加的停留时间。

6. 发明申请

WO2009008005A1 PHARMACEUTICAL COMPOSITIONS OF RIFAXIMIN 审中-公开
标题翻译： RIFAXIMIN的药物组合物
公开(公告)号：WO2009008005A1
公开(公告)日：2009-01-15
申请号：PCT/IN2008/000397
申请日：2008-06-23
申请人： LUPIN LIMITED , JAHAGIRDAR, Harshal, Anil , KULKARNI, Rajesh , KULKARNI, Shirishkumar
发明人： JAHAGIRDAR, Harshal, Anil , KULKARNI, Rajesh , KULKARNI, Shirishkumar
IPC分类号： A61K9/20 , A61K31/44
CPC分类号： A61K31/44 , A61K9/1623 , A61K9/1652 , A61K9/2086 , A61K9/2846 , A61K9/2866 , A61K9/4808 , Y02A50/473 , Y02A50/475
摘要： A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.
摘要翻译：一种药物组合物，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或其多晶型物，药学上可接受的赋形剂和释放控制剂。利福昔明的药物组合物包括：至少两个实体，其中一个实体是立即释放或快速释放，另一个实体是控制释放的。多层片剂形式的药物组合物，包含至少一层，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映体或其多晶型物，药学上可接受的赋形剂; 所述层提供受控释放的利福昔明; 以及提供剂型在胃肠道中的延长停留时间的至少一个层。包含具有体外溶出曲线的利福昔明的药物制剂，其中约70％的利福昔明在约24小时内释放。所述组合物包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或多晶型物，一种或多种释放控制剂和引起致病根除的药学上可接受的赋形剂。

7. 发明申请

WO2012028922A8 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN 审中-公开
标题翻译：控制释放的MILNACIPRAN的药物组合物
公开(公告)号：WO2012028922A8
公开(公告)日：2013-04-11
申请号：PCT/IB2011001955
申请日：2011-08-26
申请人： LUPIN LTD , KULKARNI SHIRISHKUMAR , KULKARNI RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
发明人： KULKARNI SHIRISHKUMAR , KULKARNI RAJESH , JADHAV PANDHARINATH , TIWARI ASHISH
IPC分类号： A61K31/165 , A61K9/20 , A61K9/28
CPC分类号： A61K31/164 , A61K9/209 , A61K9/2095 , A61K9/2886 , A61K9/2893 , A61K31/165 , A61K31/4178 , A61K31/439 , A61K45/00 , A61K45/06 , A61K2300/00
摘要： A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts thereof is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents.
摘要翻译：提供了包含米那普仑或其药学上可接受的盐的控释药物组合物。药物组合物包含包含米那普仑或其药学上可接受的盐，药学上可接受的赋形剂的立即释放核心和包含速率控制剂的速释核心上的包衣。

8. 发明申请

WO2011016057A2 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN 审中-公开
标题翻译：控制释放的MILNACIPRAN的药物组合物
公开(公告)号：WO2011016057A2
公开(公告)日：2011-02-10
申请号：PCT/IN2010/000520
申请日：2010-08-04
申请人： LUPIN LIMITED , KULKARNI, Shirish, Kumar , KULKARNI, Rajesh , JADHAV, Pandharinath , TIWARI, Ashish
发明人： KULKARNI, Shirish, Kumar , KULKARNI, Rajesh , JADHAV, Pandharinath , TIWARI, Ashish
IPC分类号： A61K9/20
CPC分类号： A61K9/2027 , A61K9/2013 , A61K9/2054 , A61K9/2086 , A61K9/209 , A61K9/2095 , A61K31/165
摘要： A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90 % of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carried out in 900 ml 0.1N HCl, USP apparatus Type I (Basket) at 100 rpm for 2 hrs, followed by 900 ml Phosphate buffer pH 6.8 USP apparatus Type I (Basket) at 100 rpm. A process of preparing a controlled release pharmaceutical composition comprises: a) preparing a first layer comprising i) melting hydrophobic release controlling agent and Milnacipran or pharmaceutically acceptable salts thereof in it ii) cooling followed by sieving the melted mass to obtain granules and iii) lubricating the granules; and b) preparing a second layer comprising granules which comprises hydrophobic release controlling agent and optionally Milnacipran or pharmaceutically acceptable salts thereof.
摘要翻译：包含米那普仑或其药学上可接受的盐和疏水释放控制剂的控释药物组合物。当在900ml 0.1N HCl，USP装置I型（Basket）中以100rpm进行2小时溶解时，组合物释放出总量的90％的米那普仑或其药学上可接受的盐，其时间为8至20小时，然后900 ml磷酸盐缓冲液pH 6.8 USP装置I（Basket）以100rpm。制备控释药物组合物的方法包括：a）制备第一层，其包括i）将疏水性释放控制剂和米那普兰或其药学上可接受的盐溶解在其中ii）冷却，然后筛分熔化的物质以获得颗粒，和iii）润滑颗粒; 和b）制备包含颗粒的第二层，其包含疏水性释放控制剂和任选的米那普兰或其药学上可接受的盐。

9. 发明申请

WO2009125432A3 GAS EMPOWERED EXPANDABLE DRUG DELIVERY SYSTEMS 审中-公开
公开(公告)号：WO2009125432A3
公开(公告)日：2009-10-15
申请号：PCT/IN2009/000222
申请日：2009-04-01
申请人： LUPIN LIMITED , JUNGINGER, Hans, E. , SADEGHI, Assal, M., M. , DORKOOSH, Farid , AVADI, Mohammad, Reza , RAFIEE-TEHRANI, Morteza , JADHAV, Pandharinath , KULKARNI, Rajesh , KULKARNI, Shirishkumar
发明人： JUNGINGER, Hans, E. , SADEGHI, Assal, M., M. , DORKOOSH, Farid , AVADI, Mohammad, Reza , RAFIEE-TEHRANI, Morteza , JADHAV, Pandharinath , KULKARNI, Rajesh , KULKARNI, Shirishkumar
IPC分类号： A61K9/22 , A61K9/28
摘要： An expandable drug delivery system comprising of one or more actives, force generating components, optionally containing one or more absorption modifiers and optionally containing one or more bioadhesive polymers. The active ingredient is entrapped into the nano/microsized particles of a mucoadhesive polymer matrix. The single unit dosage form is optionally coated with a degradable separating and/or enteric coating layer. An expandable drug delivery system for oral delivery consisting of a protein or peptide drug(s), force-generating components, with/with out absorption modifiers, wherein the composition is formulated to increase the residence time drug containing sub-units of the delivery system in the GIT, optionally coated with enteric polymers. An expandable drug delivery system consisting of a peptide drug, expandable polymer matrix, expanding force-generating component, which delivers drug to the absorbing membrane after a lag time followed by a burst release or sustained release.

10. 发明申请

WO2009008006A3 PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY 审中-公开
标题翻译：用于胃肠道药物递送的药物组合物
公开(公告)号：WO2009008006A3
公开(公告)日：2009-08-06
申请号：PCT/IN2008000401
申请日：2008-06-24
申请人： LUPIN LTD , JAHAGIRDAR HARSHAL ANIL , KULKARNI RAJESH , KULKARNI SHIRISHKUMAR
发明人： JAHAGIRDAR HARSHAL ANIL , KULKARNI RAJESH , KULKARNI SHIRISHKUMAR
IPC分类号： A61K9/16 , A61K9/20
CPC分类号： A61K47/44 , A61K9/0065 , A61K9/0095 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2086 , A61K9/209 , A61K31/196 , A61K31/197 , A61K31/437 , A61K31/4402 , A61K31/606 , A61K31/635 , A61K31/655 , A61K31/785 , A61K38/12 , A61K47/32 , A61K47/34 , A61K47/38
摘要： A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/ fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.
摘要翻译：一种新的药物组合物，其包含治疗有效量的活性成分或其药学上可接受的盐或对映体或多晶型物，任选的一种或多种释放控制剂和其药学上可接受的赋形剂，其中组合物被配制成增加所述药物组合物和/或活性成分在胃肠道中的停留时间。包含至少两种实体的新型药物组合物，其中一种实体是立即释放/快速释放，另一种是控制释放。包含至少两个实体的药物组合物，其中一个实体是立即释放/快速释放而另一个是生物粘附的。一种药物组合物，其包含：至少两种实体，其中一种实体是控制释放，另一种是生物粘附的。所有三种组合物都配制成增加活性成分在胃肠道中的停留时间。多层组合物，其具有提供活性成分的即时释放或控制释放的层和在胃肠道中提供增加的停留时间的层。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式